SG11201803627XA - N-substituted indole derivatives as pge2 receptor modulators - Google Patents

N-substituted indole derivatives as pge2 receptor modulators

Info

Publication number
SG11201803627XA
SG11201803627XA SG11201803627XA SG11201803627XA SG11201803627XA SG 11201803627X A SG11201803627X A SG 11201803627XA SG 11201803627X A SG11201803627X A SG 11201803627XA SG 11201803627X A SG11201803627X A SG 11201803627XA SG 11201803627X A SG11201803627X A SG 11201803627XA
Authority
SG
Singapore
Prior art keywords
gewerbestrasse
allschwil
actelion
pharmaceuticals
iii
Prior art date
Application number
SG11201803627XA
Other languages
English (en)
Inventor
Heinz Fretz
Isabelle Lyothier
Julien Pothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Peters Lorenza Wyder
Davide Pozzi
Olivier Corminboeuf
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of SG11201803627XA publication Critical patent/SG11201803627XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201803627XA 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators SG11201803627XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015077269 2015-11-20
PCT/EP2016/078028 WO2017085198A1 (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
SG11201803627XA true SG11201803627XA (en) 2018-06-28

Family

ID=57326428

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803627XA SG11201803627XA (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators

Country Status (33)

Country Link
US (2) US11241431B2 (ru)
EP (2) EP3928836A1 (ru)
JP (2) JP2018534328A (ru)
KR (1) KR102352022B1 (ru)
CN (1) CN108349949B (ru)
AU (1) AU2016358242B2 (ru)
BR (1) BR112018010291B1 (ru)
CA (1) CA3002610C (ru)
CL (1) CL2018001325A1 (ru)
CO (1) CO2018005715A2 (ru)
CR (1) CR20180323A (ru)
CY (1) CY1124913T1 (ru)
DK (1) DK3377483T3 (ru)
EA (1) EA037953B1 (ru)
ES (1) ES2897954T3 (ru)
HR (1) HRP20211678T1 (ru)
HU (1) HUE056679T2 (ru)
IL (1) IL259424B (ru)
LT (1) LT3377483T (ru)
MA (2) MA43251B1 (ru)
MX (1) MX2018005268A (ru)
MY (1) MY195888A (ru)
PE (1) PE20181304A1 (ru)
PH (1) PH12018501077B1 (ru)
PL (1) PL3377483T3 (ru)
PT (1) PT3377483T (ru)
RS (1) RS62598B1 (ru)
SA (1) SA518391588B1 (ru)
SG (1) SG11201803627XA (ru)
SI (1) SI3377483T1 (ru)
TW (2) TWI719078B (ru)
UA (1) UA123441C2 (ru)
WO (1) WO2017085198A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CN109678780A (zh) * 2017-10-19 2019-04-26 中国石油化工股份有限公司 一种制备3-烷基吲哚衍生物的方法
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
CA3124353A1 (en) * 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3693359A1 (en) 2019-02-08 2020-08-12 Medibiofarma, S.L. New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Agc株式会社 プロスタグランジンe2レセプターep2/ep4デュアルアンタゴニスト
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU3445100A (en) 2000-03-24 2001-10-08 Pharmagene Lab Ltd Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
BR0309188A (pt) 2002-04-12 2005-02-09 Pfizer Compostos pirazolo como agentes antiinflamatórios e analgésicos
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
CA2485485A1 (en) 2002-05-23 2003-12-04 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
DK1603893T3 (da) 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister
CA2536887C (en) 2003-08-26 2012-03-06 Teijin Pharma Limited Pyrrolopyrimidinone derivatives
BRPI0414130B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem.
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
WO2005105733A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
AU2007242018B2 (en) 2006-04-24 2012-07-19 Merck Canada Inc. Indole amide derivatives as EP4 receptor antagonists
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US8969394B2 (en) 2006-08-11 2015-03-03 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as EP4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
JPWO2008123207A1 (ja) 2007-03-26 2010-07-15 アステラス製薬株式会社 オルニチン誘導体
US8003661B2 (en) 2007-03-26 2011-08-23 Merck Canada Inc. Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
ATE510827T1 (de) 2007-10-12 2011-06-15 Ingenium Pharmaceuticals Gmbh Inhibitoren von proteinkinasen
WO2009105220A1 (en) 2008-02-19 2009-08-27 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
GB2474813B (en) 2008-09-19 2014-05-28 Biotechnology Res Corp Ltd Triterpenoid compounds and methods of use thereof
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
EP2504008A1 (en) 2009-11-23 2012-10-03 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
CA2806121C (en) 2010-09-21 2018-10-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
KR101857310B1 (ko) 2010-09-29 2018-05-11 가부시키가이샤 에누비 켄코우겡큐쇼 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
MX2013005535A (es) 2010-11-17 2013-07-03 Novartis Ag Compuesto de 3- (amino-aril) -piridina.
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
RU2013147417A (ru) 2011-03-24 2015-04-27 Кемилиа Аб Новые производные пиримидина
EP2702043A1 (en) 2011-04-29 2014-03-05 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
CA2839956A1 (en) 2011-06-20 2012-12-27 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
DK2729445T3 (en) 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
HUE054031T2 (hu) 2012-04-24 2021-08-30 Vertex Pharma DNS-PK inhibitorok
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
KR102194646B1 (ko) 2012-11-27 2020-12-23 토마스 헬데이스 스티프텔스 퓌어 메디신스크 포르스닝 암 치료를 위한 피리미딘-2,4-다이아민 유도체
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
HUE039015T2 (hu) 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
ES2642074T3 (es) 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Compuestos útiles como inmunomoduladores
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
PL3057959T3 (pl) 2013-10-17 2018-08-31 Vertex Pharmaceuticals Incorporated Inhibitory DNA-PK
SI3057953T1 (sl) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
EP3083554B1 (en) 2013-12-17 2019-03-13 Eli Lilly & Company Dimethylbenzoic acid compounds
WO2015094902A1 (en) 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ep4配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10052332B2 (en) 2014-04-29 2018-08-21 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US20170182003A1 (en) 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
MX2017009037A (es) 2015-01-09 2017-10-04 Ono Pharmaceutical Co Compuestos espiro triciclicos.
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3484870B1 (en) 2016-07-13 2022-11-16 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
PT3625224T (pt) 2017-05-18 2021-10-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-substituídos
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체

Also Published As

Publication number Publication date
TWI719078B (zh) 2021-02-21
PH12018501077A1 (en) 2019-01-28
TWI754397B (zh) 2022-02-01
EP3377483B9 (en) 2022-08-03
KR20180081810A (ko) 2018-07-17
JP2018534328A (ja) 2018-11-22
AU2016358242B2 (en) 2021-03-11
CA3002610A1 (en) 2017-05-26
PE20181304A1 (es) 2018-08-09
BR112018010291A2 (pt) 2018-11-06
US11241431B2 (en) 2022-02-08
MY195888A (en) 2023-02-27
MA43251A (fr) 2021-04-28
ES2897954T3 (es) 2022-03-03
US20220175775A1 (en) 2022-06-09
PT3377483T (pt) 2021-11-22
IL259424A (en) 2018-07-31
MA55046A (fr) 2021-12-29
MA43251B1 (fr) 2021-11-30
PL3377483T3 (pl) 2022-01-31
CL2018001325A1 (es) 2018-08-10
WO2017085198A1 (en) 2017-05-26
MX2018005268A (es) 2018-11-29
CY1124913T1 (el) 2023-01-05
EP3928836A1 (en) 2021-12-29
RS62598B1 (sr) 2021-12-31
CA3002610C (en) 2022-03-15
CO2018005715A2 (es) 2018-07-10
SI3377483T1 (sl) 2022-01-31
CN108349949A (zh) 2018-07-31
JP7228618B2 (ja) 2023-02-24
EA201891179A1 (ru) 2018-11-30
TW202120497A (zh) 2021-06-01
AU2016358242A1 (en) 2018-07-05
LT3377483T (lt) 2021-11-10
UA123441C2 (uk) 2021-04-07
PH12018501077B1 (en) 2019-01-28
JP2021107417A (ja) 2021-07-29
EP3377483B1 (en) 2021-09-01
EP3377483A1 (en) 2018-09-26
US20200289507A1 (en) 2020-09-17
CR20180323A (es) 2018-08-06
DK3377483T3 (da) 2021-12-06
TW201726661A (zh) 2017-08-01
KR102352022B1 (ko) 2022-01-14
IL259424B (en) 2020-11-30
BR112018010291B1 (pt) 2023-12-26
SA518391588B1 (ar) 2021-03-17
CN108349949B (zh) 2020-11-17
HUE056679T2 (hu) 2022-02-28
EA037953B1 (ru) 2021-06-11
HRP20211678T1 (hr) 2022-03-04

Similar Documents

Publication Publication Date Title
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201807426WA (en) Immunomodulators
SG11201806829TA (en) 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201908660RA (en) N-substituted indole derivatives
SG11201908097YA (en) Pyrimidine derivatives as pge2 receptor modulators
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators
SG11201909011PA (en) Niraparib compositions
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201808686VA (en) Synthesis of indazoles
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors